NKG2D (Natural Killer Group 2, Member D) ligand expression and ameloblastoma recurrence: a retrospective immunohistological pilot study.
Ameloblastoma
Cytotoxicity, immunologic
Killer cells, natural
Odontogenic tumors
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
13
03
2024
accepted:
05
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
This retrospective immunohistological pilot study aimed to investigate the influence of natural killer group 2, member D (NKG2D) ligand expression on ameloblastoma recurrence after surgical resection. It also aimed to elucidate additional clinical factors that could serve as predictors of ameloblastoma recurrence. This study included 96 patients who were histologically diagnosed with ameloblastoma after surgical resection. The expression of NKG2D ligands, including UL16-binding proteins (ULBPs) 1-3 and major histocompatibility complex class I chain-related molecule (MIC) A/B, was evaluated in formalin-fixed paraffin-embedded tumor tissues via immunohistochemistry assays. Furthermore, the patients' electronic medical records were reviewed. Multivariate Cox regression analysis was conducted, and data were expressed as adjusted hazard ratios [HRs] with 95% confidence intervals [95% CIs]. Multivariate analysis revealed that recurrent tumors (ref.: primary; adjusted HR [95% CI]: 2.780 [1.136, 6.803], p = 0.025) and positive MICA/B expression (ref.: negative; adjusted HR [95% CI]: 0.223 [0.050, 0.989], p = 0.048) independently affected recurrence-free survival in ameloblastoma. This study identified recurrent cases and loss of MICA/B expression as independent predictors of early ameloblastoma recurrence following surgical resection. The findings suggest that decreased MICA/B expression might undermine NKG2D-mediated tumor immunosurveillance, thereby influencing early recurrence.
Sections du résumé
BACKGROUND/PURPOSE
OBJECTIVE
This retrospective immunohistological pilot study aimed to investigate the influence of natural killer group 2, member D (NKG2D) ligand expression on ameloblastoma recurrence after surgical resection. It also aimed to elucidate additional clinical factors that could serve as predictors of ameloblastoma recurrence.
MATERIALS AND METHODS
METHODS
This study included 96 patients who were histologically diagnosed with ameloblastoma after surgical resection. The expression of NKG2D ligands, including UL16-binding proteins (ULBPs) 1-3 and major histocompatibility complex class I chain-related molecule (MIC) A/B, was evaluated in formalin-fixed paraffin-embedded tumor tissues via immunohistochemistry assays. Furthermore, the patients' electronic medical records were reviewed. Multivariate Cox regression analysis was conducted, and data were expressed as adjusted hazard ratios [HRs] with 95% confidence intervals [95% CIs].
RESULTS
RESULTS
Multivariate analysis revealed that recurrent tumors (ref.: primary; adjusted HR [95% CI]: 2.780 [1.136, 6.803], p = 0.025) and positive MICA/B expression (ref.: negative; adjusted HR [95% CI]: 0.223 [0.050, 0.989], p = 0.048) independently affected recurrence-free survival in ameloblastoma.
CONCLUSION
CONCLUSIONS
This study identified recurrent cases and loss of MICA/B expression as independent predictors of early ameloblastoma recurrence following surgical resection. The findings suggest that decreased MICA/B expression might undermine NKG2D-mediated tumor immunosurveillance, thereby influencing early recurrence.
Identifiants
pubmed: 39289711
doi: 10.1186/s12903-024-04873-8
pii: 10.1186/s12903-024-04873-8
doi:
Substances chimiques
NK Cell Lectin-Like Receptor Subfamily K
0
KLRK1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1102Informations de copyright
© 2024. The Author(s).
Références
Kubo H, Motohashi T, Nakano K, Horii K, Fujii T, Shoju Y, et al. Treatment of ameloblastoma and its recurrence at a single institution over a 23-year period. J Osaka Dent Univ. 2020;54:177–81.
Laborde A, Nicot R, Wojcik T, Ferri J, Raoul G. Ameloblastoma of the jaws: management and recurrence rate. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134:7–11.
pubmed: 27793625
doi: 10.1016/j.anorl.2016.09.004
Ghai S. Ameloblastoma: an updated narrative review of an enigmatic tumor. Cureus. 2022;14:e27734.
pubmed: 36127985
pmcid: 9481193
McClary AC, West RB, McClary AC, Pollack JR, Fischbein NJ, Holsinger CF, et al. Ameloblastoma: a clinical review and trends in management. Eur Arch Otorhinolaryngol. 2016;273:1649–61.
pubmed: 25926124
doi: 10.1007/s00405-015-3631-8
Au SW, Li KY, Choi WS, Su YX. Risk factors for recurrence of ameloblastoma: a long-term follow-up retrospective study. Int J Oral Maxillofac Surg. 2019;48:1300–6.
pubmed: 31084977
doi: 10.1016/j.ijom.2019.04.008
Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117:764–71.
pubmed: 20889923
doi: 10.1182/blood-2010-08-264085
Backström E, Kristensson K, Ljunggren H-G. Activation of natural killer cells: underlying molecular mechanisms revealed. Scand J Immunol. 2004;60:14–22.
pubmed: 15238069
doi: 10.1111/j.0300-9475.2004.01475.x
López-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S. NKG2D signaling in cancer immunosurveillance. Int J Cancer. 2015;136:1741–50.
pubmed: 24615398
doi: 10.1002/ijc.28775
Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55–61.
pubmed: 29525346
pmcid: 6145810
doi: 10.1016/j.coi.2018.02.004
Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, et al. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol. 2012;56:381–8.
pubmed: 21756848
doi: 10.1016/j.jhep.2011.06.017
de Kruijf EM, Sajet A, van Nes JGH, Putter H, Smit VTHBM, Eagle RA, et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012;12:24.
pubmed: 22257486
pmcid: 3292504
doi: 10.1186/1471-2407-12-24
McGilvray RW, Eagle RA, Watson NFS, Al-Attar A, Ball G, Jafferji I, et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009;15:6993–7002.
pubmed: 19861434
pmcid: 2778653
doi: 10.1158/1078-0432.CCR-09-0991
Easom NJW, Marks M, Jobe D, Gillmore R, Meyer T, Maini MK, et al. ULBP1 is elevated in human hepatocellular carcinoma and predicts outcome. Front Oncol. 2020;10:971.
pubmed: 32656081
pmcid: 7324784
doi: 10.3389/fonc.2020.00971
Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, et al. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T cells. Cancer Immunol Res. 2019;7:1813–23.
pubmed: 31484657
doi: 10.1158/2326-6066.CIR-19-0026
Ghadially H, Brown L, Lloyd C, Lewis L, Lewis A, Dillon J, et al. MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. Br J Cancer. 2017;116:1208–17.
pubmed: 28334733
pmcid: 5418453
doi: 10.1038/bjc.2017.79
Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. Diagn Pathol. 2014;9:221.
pubmed: 25432701
pmcid: 4260254
doi: 10.1186/s13000-014-0221-9
Yang R, Liu Z, Gokavarapu S, Peng C, Ji T, Cao W. Recurrence and cancerization of ameloblastoma: multivariate analysis of 87 recurrent craniofacial ameloblastoma to assess risk factors associated with early recurrence and secondary ameloblastic carcinoma. Chin J Cancer Res. 2017;29:189–95.
pubmed: 28729769
pmcid: 5497205
doi: 10.21147/j.issn.1000-9604.2017.03.04
Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710–8.
pubmed: 17182981
doi: 10.1093/aje/kwk052
Olaltan AA, Arole G, Adekeye EO. Recurrent ameloblastoma of the jaws: a follow-up study. Int J Oral Maxillofac Surg. 1998;27:456–60.
doi: 10.1016/S0901-5027(98)80037-4
Hong J, Yun PY, Chung IH, Myoung H, Suh JD, Seo B-M, et al. Long-term follow up on recurrence of 305 ameloblastoma cases. Int J Oral Maxillofac Surg. 2007;36:283–8.
pubmed: 17222535
doi: 10.1016/j.ijom.2006.11.003
Slusarenko da Silva Y, Tartaroti NA, Sendyk DI, Deboni MCZ, Naclério-Homem M. Da G. is conservative surgery a better choice for the solid/multicystic ameloblastoma than radical surgery regarding recurrence? A systematic review. Oral Maxillofac Surg. 2018;22:349–56.
pubmed: 30191338
doi: 10.1007/s10006-018-0715-9
Hresko A, Palyvoda R, Burtyn O, Chepurnyi Y, Kopchak A, Helder M, et al. Recurrent Ameloblastoma: clinical manifestation and disease-free survival rate. J Oncol. 2022;2022:2148086.
pubmed: 35983087
pmcid: 9381261
doi: 10.1155/2022/2148086
Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 2019;9:2064–78.
pubmed: 31720075
pmcid: 6834480
Malmberg KJ, Carlsten M, Björklund A, Sohlberg E, Bryceson YT, Ljunggren HG. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:20–9.
pubmed: 28888619
doi: 10.1016/j.smim.2017.08.002
Jeon S, Kim HK, Kwon JY, Baek SH, Ri HS, Choi HJ, et al. Role of Sevoflurane on Natural Killer Group 2, Member D-Mediated Immune Response in Non-small-cell Lung Cancer: an in Vitro Study. Med Sci Monit. 2020;26:e926395.
pubmed: 33139690
pmcid: 7648410
doi: 10.12659/MSM.926395
Sheppard S, Ferry A, Guedes J, Guerra N. The paradoxical role of NKG2D in Cancer Immunity. Front Immunol. 2018;9:1808.
pubmed: 30150983
pmcid: 6099450
doi: 10.3389/fimmu.2018.01808
Schmiedel D, Mandelboim O. NKG2D ligands-critical targets for Cancer Immune escape and therapy. Front Immunol. 2018;9:2040.
pubmed: 30254634
pmcid: 6141707
doi: 10.3389/fimmu.2018.02040
Tan G, Spillane KM, Maher J. The role and regulation of the NKG2D/NKG2D ligand system in Cancer. Biology. 2023;12:1079.
pubmed: 37626965
pmcid: 10452210
doi: 10.3390/biology12081079
Ma Y, Li X, Kuang E. Viral evasion of natural killer cell activation. Viruses. 2016;8:95.
pubmed: 27077876
pmcid: 4848590
doi: 10.3390/v8040095
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and Cancer: a current overview of Epidemiology, Pathogenesis, outcomes, and management. Cancers. 2023;15:485.
pubmed: 36672434
pmcid: 9857053
doi: 10.3390/cancers15020485
Yap A, Lopez-Olivo MA, Dubowitz J, Hiller J, Riedel B, Wigmore T, et al. Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019;66:546–61.
pubmed: 30834506
doi: 10.1007/s12630-019-01330-x
Soltanizadeh S, Degett TH, Gögenur I. Outcomes of cancer surgery after inhalational and intravenous anesthesia: a systematic review. J Clin Anesth. 2017;42:19–25.
pubmed: 28797751
doi: 10.1016/j.jclinane.2017.08.001
Kim HJ, Jeon S, Lee HJ, Bae J, Ri HS, Hong JM, et al. Effects of sevoflurane on metalloproteinase and natural killer group 2, member D (NKG2D) ligand expression and natural killer cell-mediated cytotoxicity in breast cancer: an in vitro study. Korean J Anesthesiol. 2023;76:627–39.
pubmed: 37435613
pmcid: 10718625
doi: 10.4097/kja.23323
Hendra FN, Van Cann EM, Helder MN, Ruslin M, de Visscher JG, Forouzanfar T, et al. Global incidence and profile of ameloblastoma: a systematic review and meta-analysis. Oral Dis. 2020;26:12–21.
pubmed: 30614154
doi: 10.1111/odi.13031
Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. Guidance for Industry and Food and Drug Administration Staff. USA: Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Center for Biologics Evaluation and Research Center for Drug Evaluation and Research. 2013 https://www.fda.gov/files/medical%20devices/published/Distribution-of-In-Vitro-Diagnostic-Products-Labeled-for-Research-Use-Only-or-Investigational-Use-Only---Guidance-for Industry-and-FDA-Staff.pdf [Date assessed: January 2, 2024].
Cadavid AMH, Araujo JP, Coutinho-Camillo CM, Bologna S, Junior CAL, Lourenço SV. Ameloblastomas: current aspects of the new WHO classification in an analysis of 136 cases. Surg Experimental Pathol. 2019;2:1–6.
doi: 10.1186/s42047-019-0041-z